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Abstract
Background: A two-step tuberculin skin test (TST) should be performed if the subsequent TSTs are to be conducted at regular inter-
vals, especially among health care professionals, and its interpretation of serial TST is particularly complex.
Methods: In this randomized controlled clinical trial, the effect of fish oil fatty acid (FA) supplementation on two-step TST was in-
vestigated. The outcome was considered a change in 2 sequential TST induration sizes; 6 mm or more were considered as a criterion
to distinguish the increase in reaction size. The study protocol was approved in the ethic committee of Qazvin University of Medi-
cal Sciences. In the present study, 213 healthy participants (medical and nursing students of Qazvin University of Medical Sciences
in 2014) were randomly assigned into a normal diet (control) or fish oil supplementation (treatment) group. One gram of fish oil
supplement was given to the treatment group daily for 5 consecutive days.
Results: The mean secondary induration and the difference between the primary and secondary induration sizes were significantly
higher in the fish oil users (P < 0.001). Noticeable increase in TST size in the treatment group was significantly higher than in the
control (16.3% vs. 1.2%).
Conclusions: Short-term supplementation with fish oil FAs seems to increase the accuracy of two-step TST.
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1. Background
Tuberculin skin test (TST) has been widely used to de-
termine any immunological reactivity to mycobacterial
antigens (1). Because the health care workers (HCWs) are
vulnerable to tuberculosis (TB) infection, they are screened
with TST to identify latent TB infection (2, 3) although 10%
to 20% of TB patients show negative results on TST (without
immunosuppression) (4). Hence, HCWs, who have under-
gone annual tuberculin skin testing, are recommended to
do a two-step testing on initial evaluation, with a second
TST 1 week after a negative initial test (1). Tuberculin reac-
tions may decrease or increase in size due to immunologic
recall of pre-existing delayed type hypersensitivity to my-
cobacterial antigens, or new infection (5).
Two-step tuberculin testing is an essential tool for iden-
tifying persons with the baseline positive tuberculin test
results and allows accurate reporting of subsequent HCW
tuberculin conversions (6). HCWs are much more likely
to have boosting than conversion, except in case of the
initial two-step testing pre-exposure (1). In other words,
two-step initial TST may help eliminate nearly 80% of false-
positive conversions; nevertheless, interpretation of re-
peated TST results is difficult because of the nonspecific
variations in test results (7, 8). Some studies demonstrated
that some factors are associated with a boost; eg, age, in-
fection with atypical mycobacteria, and previous Bacillus
Calmette-Guerin (BCG) vaccination (1).
Animal studies have suggested that a boosted skin test
response correlates with the serum immunoglobulin G re-
actions against a range of mycobacterial antigen prolifer-
ative responses (9). However, the effect of immunomodu-
lator supplements on the skin test results is uncertain. The
omega-3 fish oil contains both docosahexaenoic acid (DHA)
and eicosapentaenoic acid (EPA). The “n-3” fatty acids (FA)
that are essential nutrients are known as regulators of in-
flammation (10). Epidemiological studies have shown the
benefits of fish oil in inflammation-associated pathologies
(10, 11). There are controversial reports about the effects of
fish oil FA on T cell immune function in humans. Some
studies found the deficiency of (n-3) FA as a contributing
factor to cutaneous anergy, but in other studies DHA sup-
plementation resulted in no effects on delayed-type hyper-
sensitivity (DTH) skin response (12).
Those controversies will raise questions about the ef-
fect of fish oil consumption on tuberculin test (a DTH re-
sponse that shows cutaneous reaction to purified protein
derivative (PPD) as a manifestation of cell-mediated immu-
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nity). This study aimed at responding to this question and
determining the effect of the short duration fish oil FA con-
sumption on two-step TST results in young healthy medical
and nursing student volunteers.
2. Methods
2.1. Study Design, Setting, and Population
In the present study, the entire population was used as
the sample. A census is attractive for small populations (eg,
200 or less), eliminates sampling error, and provides data
on all the individuals in the population (13). All students
from medical and nursing schools of Qazvin University of
Medical Sciences (QUMS) (n = 213) were invited to partic-
ipate in this study. Those volunteers who did not have
evidence of tuberculosis were enrolled. Exclusion crite-
ria included any type of known allergies, clinical disorder,
and consumption of immunosuppressive medications, or
steroida1 anti-inflammatory drugs. Information on demo-
graphics, some anthropometric indices, history of expo-
sure to TB, family size, and smoking were gathered using a
questionnaire. This study was registered in the Iranian reg-
istry of clinical trials (IRCT), with a registration number of
IRCT2015040620882N2.
2.2. Intervention and Study Outcomes
Participants were randomly assigned into a conven-
tional diet (control), or fish oil (treatment) group us-
ing computerized simple randomization. Computer-
generated random-numbers software was used to gener-
ate a random allocation sequence. The researcher who was
in charge of reading the second TST was blind to group
assignment. TST have been carried out at baseline and 1
week after the initial inoculation (in 2 periods between De-
cember 1 - 8, 2013, and May 9 - 16, 2014). The second TST
was applied for all participants in both groups, except for
the 36 dropped outs. The daily intervention in the treat-
ment group consisted of 1 gram fish oil soft gel capsule
which contained 180 mg EPA and 120 mg DHA FAs, man-
ufactured by biotech USA International Corporation Ltd.
The selected dose is the minimum limit of fish oil supple-
mentation with physiological effects and without any toxi-
city (14). The capsules were given for 5 consecutive days be-
cause according to an expert panel, the probability of con-
tinuous consumption of supplements may decrease after
the first week.
The outcome of the trial was a change in 2 sequential
(primary and secondary) purified protein derivative test
(PPD) induration sizes. Six mm or more were considered
as a criterion to distinguish increases in reaction size due
to random variation alone from true biologic phenomena
(1, 15, 16).
DTH skin test was performed at the baseline and after
1 week. The DTH skin test is an in vivo indicator of spe-
cific cell-mediated immune responsiveness by T cells. Tu-
berculin testers were trained according to standard guide-
lines (17). All participants were tested with 0.1 mL 5TU-
PPD (5 tuberculin units of PPD; Razi institute, Tehran, Iran).
The PPD injected intradermally on the volar aspect of the
left forearm. The site of injection was marked with a felt
marker. All tuberculin solutions were stored in the vaccine
carriers at 2 - 6°C over the period of study. The tests were
read after approximately 48 hours. The maximum trans-
verse diameter of induration (not erythema) was mea-
sured with a ruler for each participant.
2.3. Ethical Considerations
The participants freely participated in this clinical trial
and could withdraw from the study at any time they
wished. The ethics committee of the QUMS approved the
study. Written informed consent was obtained from each
participant.
2.4. Statistical Analysis
Continuous variables were summarized as means ±
standard deviation (SD) and categorical variables as fre-
quencies and percentages, unless otherwise stated. The
treatment group was compared to the control using Chi-
square and Fisher’s exact tests for nominal, and student’s t
test for continuous variables. The association between lev-
els of change in skin test reactivity and exposure was eval-
uated by Chi-square test. Binary logistic regression anal-
ysis was done to assess the effect of fish oil consumption
on the secondary induration size status. Moreover, linear
regression analysis was used to assess the effect of fish oil
consumption on the difference between the secondary and
primary induration sizes. Pearson Chi-square test was con-
ducted to examine the relationships. SPSS for Windows,
Version 21 (SPSS Inc., Chicago, IL) was used for statistical
analyses. P-value of < 0.05 was considered as statistically
significant.
3. Results
In the present study, 213 students of QUMS were consid-
ered for inclusion, 36 (17%) of them refused to receive their
second shot. Thus, 177 students, aged 18 - 46 years were ran-
domly allocated into treatment (1 gram fish oil soft gel cap-
sule) and control groups (Figure 1).
The participants had a mean age of 21.58± 4.50 years
(Range: 18 - 46) and nearly 2/3 (65%) of them were female.
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Figure 1. Trial Profile
Randomized groups did not show any difference in age,
body mass index (BMI), first induration size, family size,
smoking status, and gender before the intervention (Table
1).
Table 1. Comparing Baseline Characteristics of the Participants Between the Two
Groupsa
Variables Group P Value
Treatment Control
Age, y 21.92± 3.30 21.20± 1.53 0.066b
BMI, kg/m2 22.60± 3.05 22.57± 3.04 0.947b
Family size 4.17± 1.43 4.40± 1.50 0.305b
First induration size, mm 4.17± 4.81 4.52± 4.17 0.613b
Male, % 33.7 36.5 0.700c
Smoker, % 6.5 1.2 0.120d
Abbreviations: BMI, Body Mass Index; SD, Standard Deviation.
aValue are expressed as Mead± SD.
bStudent t test.
cPearson Chi-square.
dFisher’s exact test.
All participants had already been vaccinated against TB
with BCG vaccine and were determined to be free of any
chronic systemic disease. Seven participants had a known
history of TB contact. No adverse events were reported
in the treatment group during the course of the study.
The mean secondary induration was significantly higher
in fish oil users than in controls (6.68 ± 0.70 vs. 3.61 ±
0.42), as well as the difference between the primary and
secondary induration sizes (2.51±0.52 vs. -0.91±0.34) (P <
0.001). The proportion of an increasing size of TST indura-
tion in the intervention group was higher (16.3 vs. 1.2%) (Ta-
ble 2).
Table 2. Tuberculin Skin Test Variation in the Two Groupsa
Induration Level Group Number Total
Treatment Control
Significant decrease in sizeb 5 (5.4) 8 (9.4) 13 (7.3)
Unaffected 72 (78.3) 76 (89.4) 148 (83.6)
Significant increase in sizeb 15 (16.3) 1 (1.2) 16 (9.0)
Total 92 (100.0) 85 (100.0) 177 (100.0)
aValue are expressed as N. (%).
bSix mm or more, (Chi-square, 12.8; P < 0.01).
To assess the contributors of induration size change,
we entered consumption of fish oil, age, sex, BMI, first in-
duration size, family size, history of TB contact, and smok-
ing into the binary logistic regression model. After enter-
ing the method analysis, consumption of fish oil and first
induration size remained in the model. Increasing age was
another contributor for induration difference (Table 3).
4. Discussion
The present study aimed at providing a better under-
standing of the previously observed effects associated with
fish oil supplementation and examining the impact of fish
oil FAs on the immune system function of healthy volun-
teers. This was one of the few studies reporting the effects
of short-term fish oil FAs on cellular immune response of
healthy individuals. In our study, fish oil consumption af-
fected the DTH reaction in healthy participants (18, 19).
In our study in the two- step TST of healthy individu-
als, a significant increase in the size of TST induration was
a rare phenomenon (1.2%), but with administration of fish
oil, this increased to 16.3%. Our results revealed that the
short-term intake of n-3 fatty acid may increase the abil-
ity to respond to tuberculin antigen that are in accordance
with human trials reporting increased T cell-mediated im-
mune responsiveness (20). Most animal studies (mainly
containing a high level of FA or a long-term consumption)
have indicated that fish oil FAs suppress the immune re-
sponses both in vivo and in vitro (21-24). In addition, in
some human reports, high level or long time dietary fish
oil impairs lymphocyte responses (12). In our study, a de-
creasing size of TST induration in the treatment group was
not significantly different between the 2 groups (5.4% vs.
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Table 3. Factors Influencing the Induration Difference (Linear Regression, Method = Enter)
Variables Standardized P Value 95% CI for B
Coefficients Beta Lower Upper
First induration size -0.281 0.004a -0.346 -0.068
Age 1.758 0.001a 0.159 0.586
Group -1.064 0.000a -4.355 -1.917
BMI -0.497 0.274 -0.281 0.080
Sex 0.384 0.107 -0.226 2.287
Smoking 0.117 0.857 -2.736 3.286
Contact with TB+ -0.345 0.587 -3.729 2.117
Abbreviations: BMI, Body Mass Index; CI, Confidence Interval; TB, Tuberculosis.
aPredictors in the Model: first induration size, age and group. Negative values of beta indicate a reverse association
9.4%). The results of our study are different from those of
some previously reported studies. Kelley et al. found that
supplementation of healthy young men with DHA would
result in no effects on DTH skin response (25). However,
there are differences in experimental designs and methods
between the studies, which may account for those varia-
tions.
With increasing age, induration size of TST (resulting
from mycobacterial infection) may decline in some people
and result in a nonreactive TST (26) although in our study,
the high first induration size and the highest increasing
size of TST induration belonged to the older students. The
most likely explanation for this is “natural boosting”. My-
colyl transferase is present in BCG and exists in all my-
cobacterial species, thus, allowing the natural boosting of
specific immune responses via environmental exposure to
even nonpathogenic mycobacteria (27). Evidence of natu-
ral boosting has been demonstrated in TB endemic areas
(28).
In the present study, increased size of TST induration
was observed in a few nonreactive participants (1.2%) in the
control group after the second TST. A probable reason is
“booster phenomenon” or increased size of the reaction to
second test administered 1 week after the primary TST. Sim-
ilarly, the results of another study indicated a reactivity en-
hancement in only a minority of serial tests with PPD anti-
gen (1).
This study had some limitations. First, our results were
not adequate to definitively confirm an important role of
the two- step TST concurrent omega- 3 consumption strate-
gies in a different clinical context. Second, we studied a
limited population of students in a university; therefore,
further large-scale validation studies have to be conducted
before recommending or applying this strategy even in a
similar setting. Although participants were not blinded to
the type of treatment (fish oil taste), the readout TST results
were quantitative and the criteria for a positive response
were predefined.
4.1. Conclusions
In summary, age and fish oil consumption were iden-
tified as the most important independent contributors of
TST induration size in two-step testing. Overall, our results
suggest that a short-term supplementation with fish oil
FAs may improve the ability of healthy volunteers to re-
spond effectively to antigens of mycobacterium tubercu-
losis and likely increase the accuracy of two-step TST. Nev-
ertheless, we believe that the more comprehensive studies
with different terms and dosages should be carried out to
better evaluate the effect of fish oil consumption on two-
step TST results. Ideally, a large prospective study is needed
to verify and elucidate the association between fish oil con-
sumption and TST size changes.
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